Source: Actinium Pharmaceuticals, Inc.
Director of Clinical Operations brings nearly two decades of clinical development and pharmaceutical industry experience to Actinium
Actinium
Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a
biopharmaceutical Company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, announced
today the appointment of Gregory Bergonio, M.S.H.S., to the position of
Director of Clinical Operations. Mr. Bergonio’s initial responsibility
will be focusing on the advancement of the Actimab-A Phase 2 clinical
trial as well as earlier stage clinical programs that the company plans
to undertake.
“We are very excited to
welcome Greg to the clinical development team at Actinium,” said Sandesh
Seth, Actinium’s Executive Chairman. “Greg’s joining comes at an ideal
time given our increased development efforts as a result of the
Actimab-A Phase 2 trial and Iomab-B pivotal Phase 3 SIERRA trial. Greg’s
direct experience in AML and significant knowledge of clinical trial
management will have an immediate impact on our capabilities that we
expect will add efficiency and scale to our current and planned clinical
development efforts.”
Most recently, Mr.
Bergonio worked at Novartis as an expert clinical manager in their
oncology global development unit with a focus on acute myeloid leukemia
(AML). At Novartis, Greg managed a wide array of clinical development
activities focused on driving effective operations at clinical trials
sites on an international basis. In addition, he coordinated
interdisciplinary efforts focused on inspection preparation activities
associated with the new drug application (NDA) submissions at the site
and sponsor level. Prior to Novartis, Greg worked at a number of large
multi-national pharmaceutical companies and CROs including Bausch &
Lomb, OSI, Forest Laboratories, Inc. and Kern McNeill International
where he gained experience in the therapeutic areas of oncology,
cardiology, CNS and ophthalmology. Greg has a Master of Science Degree
in Health Sciences with a focus on Clinical Research Administration from
George Washington University and a Bachelor of Science Degree in
Nursing from Fairleigh Dickinson University.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative
targeted therapies for cancers lacking effective treatment options.
Actinium's proprietary platform utilizes monoclonal antibodies to
deliver radioisotopes directly to cells of interest in order to kill
those cells safely and effectively. The Company's lead product candidate
Iomab-B is designed to be used, upon approval, in preparing patients
for a hematopoietic stem cell transplant, commonly referred to as bone
marrow transplant. A bone marrow transplant is often the only potential
cure for patients with blood-borne cancers but the current standard
preparation for a transplant requires high-dose chemotherapy and/or
total body irradiation that result in significant toxicities. Actinium
believes Iomab-B will enable a faster and less toxic preparation of
patients seeking a bone marrow transplant, leading to increased
transplant success and survival rates. The Company is currently
conducting a single pivotal 150-patient, multicenter Phase 3 clinical
study of Iomab-B in patients with relapsed or refractory acute myeloid
leukemia (AML) age 55 and older. The Company's second product candidate,
Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2
trial for patients newly diagnosed with AML age 60 and over. Actimab-A
is being developed to induce remissions in elderly patients with AML who
lack effective treatment options and often cannot tolerate the
toxicities of standard frontline therapies. Actinium is also utilizing
its alpha-particle immunotherapy (APIT) technology platform to generate
new drug candidates based on antibodies linked to the element
Actinium-225 that are directed at various cancers that are blood-borne
or form solid tumors.
No comments:
Post a Comment